Vaccination Response Modulation With a Targeted Rapamycin Protocol Study
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age60+
SponsorCentral Adelaide Local Health Network Incorporated
About this trial
This study will investigate dialysis recipients' responses to important vaccines.
Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.
Eligibility criteria
Qualifiers
End-stage kidney disease requiring in-centre haemodialysis three times per week as kidney replacement therapy
Aged >60 years
Disqualifiers
Aged <60 years
Alternative haemodialysis regimens (e.g. twice-weekly haemodialysis, second-daily home haemodialysis)
Recent infection (<6 months) with proven Influenza A, Influenza B, or RSV
Oral steroid at a dose equivalent of 5 mg/day prednisolone or greater
Trial design
Treatments tested in this trial
- Sirolimus (RAPAMUNE)
- Influenza vaccine (Sequiris Fluad Quad)
- RSV vaccine (Pfizer Abrysvo)
Treatment groups
60 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov